Evidence map›Paper›PMID 36245284›Full record

ArticleClinical and translational medicine2022

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.

Gehan Xu, Liang Cui, Jin Li, Quanren Wang, Pansong Li, Xuefeng Xia, Xin Yi, Quanlin Guan, Jianming Xu

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Gehan XuThe First Clinical Medical College of Lanzhou University, Lanzhou, China.
Liang CuiGeneplus-Beijing Institute, Beijing, China.ORCID 0000-0002-4785-9678
Jin LiGeneplus-Beijing Institute, Beijing, China.
Quanren WangJiangsu Hengrui Medicine Co. Ltd., Jiangsu, China.
Pansong LiGeneplus-Beijing Institute, Beijing, China.ORCID 0000-0002-6278-5179
Xuefeng XiaGeneplus-Beijing Institute, Beijing, China.
Xin YiGeneplus-Beijing Institute, Beijing, China.
Quanlin GuanDepartment of Oncology Surgery, The First Hospital of Lanzhou University, Lanzhou, China.
Jianming XuDepartment of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.ORCID 0000-0003-4467-6021
First Hospital of Lanzhou University · CNChinese PLA General Hospital · CNJiangsu Hengrui Medicine (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedHumansImmune Checkpoint InhibitorsPrognosisPyridinesAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedapatinibcamrelizumabImmune Checkpoint InhibitorsPyridinesangiogenic inhibitorsbiomarkerhepatocellular carcinomaimmune checkpoint inhibitorsprognosis

Identifiers

PMID36245284
PMCPMC9574487
OpenAlexW4306393539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.